Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

9 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Targeting TRAIL death receptors.
Oldenhuis CN, Stegehuis JH, Walenkamp AM, de Jong S, de Vries EG. Oldenhuis CN, et al. Curr Opin Pharmacol. 2008 Aug;8(4):433-9. doi: 10.1016/j.coph.2008.06.011. Epub 2008 Jul 28. Curr Opin Pharmacol. 2008. PMID: 18625341 Review.
Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients.
Koornstra JJ, Rijcken FE, Oldenhuis CN, Zwart N, van der Sluis T, Hollema H, deVries EG, Keller JJ, Offerhaus JA, Giardiello FM, Kleibeuker JH. Koornstra JJ, et al. Among authors: oldenhuis cn. Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1608-12. doi: 10.1158/1055-9965.EPI-05-0112. Cancer Epidemiol Biomarkers Prev. 2005. PMID: 16030090 Free article.
Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.
Mom CH, Verweij J, Oldenhuis CN, Gietema JA, Fox NL, Miceli R, Eskens FA, Loos WJ, de Vries EG, Sleijfer S. Mom CH, et al. Among authors: oldenhuis cn. Clin Cancer Res. 2009 Sep 1;15(17):5584-90. doi: 10.1158/1078-0432.CCR-09-0996. Epub 2009 Aug 18. Clin Cancer Res. 2009. PMID: 19690193 Free article. Clinical Trial.
Targeting TRAIL towards the clinic.
Mahalingam D, Oldenhuis CN, Szegezdi E, Giles FJ, de Vries EG, de Jong S, Nawrocki ST. Mahalingam D, et al. Among authors: oldenhuis cn. Curr Drug Targets. 2011 Dec;12(14):2079-90. doi: 10.2174/138945011798829357. Curr Drug Targets. 2011. PMID: 21777191
Translating TRAIL-receptor targeting agents to the clinic.
den Hollander MW, Gietema JA, de Jong S, Walenkamp AM, Reyners AK, Oldenhuis CN, de Vries EG. den Hollander MW, et al. Among authors: oldenhuis cn. Cancer Lett. 2013 May 28;332(2):194-201. doi: 10.1016/j.canlet.2012.04.007. Epub 2012 Apr 21. Cancer Lett. 2013. PMID: 22531313 Review.
Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors.
Sharma S, de Vries EG, Infante JR, Oldenhuis CN, Gietema JA, Yang L, Bilic S, Parker K, Goldbrunner M, Scott JW, Burris HA 3rd. Sharma S, et al. Among authors: oldenhuis cn. Invest New Drugs. 2014 Feb;32(1):135-44. doi: 10.1007/s10637-013-9952-9. Epub 2013 Apr 16. Invest New Drugs. 2014. PMID: 23589214
A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignancies.
Oldenhuis CN, Loos WJ, Esteves B, van Doorn L, Cotreau MM, Strahs AL, den Hollander MW, Gietema JA, de Vries EG, Eskens FA. Oldenhuis CN, et al. Clin Colorectal Cancer. 2015 Mar;14(1):18-24.e1. doi: 10.1016/j.clcc.2014.12.001. Epub 2014 Dec 16. Clin Colorectal Cancer. 2015. PMID: 25591799 Clinical Trial.
Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.
Schraa SJ, van Rooijen KL, van der Kruijssen DEW, Rubio Alarcón C, Phallen J, Sausen M, Simmons J, Coupé VMH, van Grevenstein WMU, Elias S, Verkooijen HM, Laclé MM, Bosch LJW, van den Broek D, Meijer GA, Velculescu VE, Fijneman RJA, Vink GR, Koopman M; PLCRC-MEDOCC group. Schraa SJ, et al. BMC Cancer. 2020 Aug 20;20(1):790. doi: 10.1186/s12885-020-07252-y. BMC Cancer. 2020. PMID: 32819390 Free PMC article.